Tumor-induced osteomalacia: A case of diagnostic dilemma

被引:11
作者
Robertson, Andrew
Mansberg, Robert [1 ]
Mansberg, Victor
Van der Wall, Hans
Hooper, Michael
机构
[1] Concord Hosp, Dept Nucl Med, Concord, NSW 2139, Australia
[2] Univ Sydney, Discipline Med, Sydney, NSW 2006, Australia
关键词
tumor-induced osteomalacia; thyroid; parathyroid; adrenal; octreotide;
D O I
10.1097/RLU.0b013e3180a1ad1d
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Tumor-induced osteomalacia is typically caused by benign mesenchymal tumors of vascular or skeletal origin. Overexpression of fibroblast growth factor 23 (FGF-23) by these tumors is associated with decreased resorption of phosphate in the renal tubules. This phosphate wasting leads to the characteristic findings of hypophosphatemia and hyperphosphaturia. Chronic hypophosphatemia causes abnormal mineralization of bone, increased alkaline phosphatase and, in the longer term, osteomalacia. Localization and resection of the FGF-23-secreting tumor offers the best chance of cure. We report a case of a 74-year-old woman diagnosed with numerous fractures on bone scintigraphy. Bone biopsy confirmed osteomalacia. Biochemical investigations showed hypophosphatemia, hyperphosphaturia, and increased alkaline phosphatase, suggesting the presence of an FGF-23-secreting tumor. Biochemistry also showed hyperparathyroidism and subclinical hyperthyroidism. Thyroid and parathyroid scintigraphy were performed and showed separate areas of focally increased tracer uptake in the neck. The patient underwent octreotide scintigraphy to localize an alternative site of tumor. This showed focally increased tracer uptake in the neck and in the abdomen. The patient under-went a hemithyroidectomy, parathyroidectomy, and adrenalectomy. Histopathology showed a papillary carcinoma of the thyroid, a parathyroid adenoma, and an adrenal adenoma. Postoperatively the patient showed rapid symptomatic and biochemical improvement.
引用
收藏
页码:631 / 634
页数:4
相关论文
共 9 条
[1]   Tumor-Induced Osteomalacia [J].
Drezner M.K. .
Reviews in Endocrine and Metabolic Disorders, 2001, 2 (2) :175-186
[2]   Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin [J].
Fukumoto, S ;
Yamashita, T .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (04) :385-389
[3]   Bone and In-111 octreotide imaging in oncogenic osteomalacia - A case report [J].
Garcia, CA ;
Spencer, RP .
CLINICAL NUCLEAR MEDICINE, 2002, 27 (08) :582-583
[4]  
Marian-Balasa M, 2001, WORLD MUSIC, V43, P259
[5]   Coexisting hyperparathyroidism and oncogenic osteomalacia: Sestamibi and somatostatin receptor scintigraphy [J].
Nguyen, Ba D. .
CLINICAL NUCLEAR MEDICINE, 2006, 31 (10) :648-651
[6]   Tumor-induced osteomalacia: A case of diagnostic dilemma [J].
Robertson, Andrew ;
Mansberg, Robert ;
Mansberg, Victor ;
Van der Wall, Hans ;
Hooper, Michael .
CLINICAL NUCLEAR MEDICINE, 2007, 32 (08) :631-634
[7]   Octreotide therapy for tumor-induced osteomalacia [J].
Seufert, J ;
Ebert, K ;
Müller, J ;
Eulert, J ;
Hendrich, C ;
Werner, E ;
Schütze, N ;
Schulz, G ;
Kenn, W ;
Richtmann, H ;
Palitzsch, KD ;
Jakob, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (26) :1883-1888
[8]   Oncogenic osteomalacia [J].
Sundaram, M ;
McCarthy, EF .
SKELETAL RADIOLOGY, 2000, 29 (03) :117-124
[9]   Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia [J].
Yamazaki, Y ;
Okazaki, R ;
Shibata, M ;
Hasegawa, Y ;
Satoh, K ;
Tajima, T ;
Takeuchi, Y ;
Fujita, T ;
Nakahara, K ;
Yamashita, T ;
Fukumoto, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) :4957-4960